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human fetal thymic tissue plus hematopoietic stem cells transduced with a leukemia-associated fusion gene
MLL-AF9. In addition to normal human lymphohematopoietic reconstitution as seen in non-leukemic hu-mice,
these hu-mice showed spontaneous development of B-cell acute lymphoblastic leukemia (B-ALL), which was
transplantable to secondary recipients with an autologous human immune system. Using this model, we show
that lymphopenia markedly improves the antitumor efﬁcacy of recipient leukocyte infusion (RLI), a GVHD-free
immunotherapy that induces antitumor responses in association with rejection of donor chimerism inmixed al-
logeneic chimeras. Our data demonstrate the potential of this leukemic hu-mouse model in modeling leukemia
immunotherapy, and suggest that RLI may offer a safe treatment option for leukemia patients with severe
lymphopenia.





Mixed-lineage leukemia fusion gene
Recipient leukocyte infusion1. Introduction
Mousemodels are themost commonly used in vivo systems for can-
cer studies, in which immunotherapy can be studied in immunological-
ly intact syngeneic hosts. However, because of the many differences
between rodents and humans, much of the information on both patho-
genesis and immunotherapies learned from the conventional mouse
models cannot be applied to humans. For this reason, xenograft models
have been increasingly used to study human tumors. In this model,
human tumors can be grafted and grow in immunodeﬁcient mice that
lack immune system. To study interaction between the tumor and im-
mune system, human peripheral blood mononuclear cells (PBMCs) or
T cells were transferred into the immunodeﬁcient mice bearing
human tumors. However, the immune responses are not physiological
for two reasons. First, xenoantigen-reactive T cells in the injected
human cells cause graft-vs.-host responses. Second, because human an-
tigen-presenting cells (APCs) are lacking, such system can neithermain-
tain peripheral T cell pool nor initiate human leukocyte antigen (HLA)-
restricted immune responses.ational Immunology, Columbia
est 168th St, BB15-1501, New
. This is an open access article underFunctional human hematopoietic and lymphoid systems can be
established in mice by transplantation of human fetal thymic tissue
(FTHY) and CD34+ fetal liver cells (FLCs) to sublethally-irradiated im-
munodeﬁcient mice (Lan et al., 2006; Lan et al., 2004; Melkus et al.,
2006). These hu-mice have proved to be an excellent model for
assessing human innate and adaptive immune responses in vivo
under normal or pathological conditions such as human immune re-
sponses to allo- and xeno-antigens and viral infection (Hu and Yang,
2012). Here, we seek to develop hu-mice with human
lymphohematopoietic systems and autologous leukemia that permit
exploration of human cancer immunotherapy.
2. Materials and Methods
2.1. Animals and Human Tissues and Cells
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD/SCID/γc−/− or NSG) mice
were purchased from the Jackson Laboratory (Bar Harbor, ME), and
were housed in a speciﬁc pathogen-free micro-isolator environment
and used in experiments at 6 to 10 weeks of age. Human fetal thymus
and liver tissues of gestational age of 17 to 20 weeks were obtained
from Advanced Bioscience Resource (Alameda, CA). Thymic tissue was
cut into small fragments measuring about 1 mm3; human CD34+ fetal
liver cells (FLCs) were puriﬁed by a magnetic-activated cell sorterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CA). The prepared human thymic tissue fragments and CD34+ FLCs
were then cryopreserved in liquid nitrogen until use. Protocols involv-
ing the use of human tissues and animals were approved by the
Human Research Committee and the Institutional Animal Care and
Use Committee of Columbia University.2.2. Retroviral Transduction of CD34+ FLCs
Pseudo-typed retroviruses were produced by transfection using
Lipofectamine 2000 (Invitrogen, San Diego, CA) of 293FT cells with
a 3-plasmid system consisting of the MLL fusion vector (MSCV-
MLL-AF9-human pgk-EGFP; kindly provided by Dr. John Dick)
(Barabe et al., 2007) and two packaging vectors (VSV-G and Psi-
Env). Viral particles were collected 48 or 72 h post-transfection and
concentrated by ultracentrifugation at 50,000 g for 2 h, and were
titered and stored at −80 °C until use. For transduction, human
CD34+ FLCs were stimulated overnight in medium containing
50 ng/mL rhSCF (R&D, Minneapolis, MN), 50 ng/mL Flt-3L
(eBioscience, San Diego, CA), 25 ng/mL TPO (R&D, Minneapolis,
MN), 10 ng/mL IL-3 (R&D, Minneapolis, MN), in 24-well plates pre-
coated with Retronectin (Takara Bio Inc.), followed by incubation
with retroviruses for 12 h. Cells were washed twice and injected
into sublethally irradiated NSG mice to generate leukemic hu-mice
(see Hu-mouse preparation below). A small aliquot of the trans-
duced cells was cultured for 3 additional days to determine the
transduction efﬁciency by measuring the ratio of GFP+ cells using
FACS (ranged between 10 and 30% in the experiments presented).2.3. Humanized Mouse Preparation
NSGmice were conditioned with sublethal (2 Gy) total body irra-
diation (TBI), and transplanted intravenously (i.v.) or intrafemorally
(i.f.) with human CD34+ FLCs (0.5–2 × 105/mouse) alone or along
with thymic tissue fragment measuring about 1 mm3 (under
mouse kidney capsule) from the same fetal donor, as previously de-
scribed (Lan et al., 2006; Tonomura et al., 2008). Levels of human he-
matopoietic cells in hu-mice were determined by ﬂow cytometric
analysis using various combinations of the following mAbs: anti-
human CD45, CD3, CD4, CD8, CD45RA, CD45RO, CD19, CD20, CD10,
IgM, IgD, CD44, CD33, CD14, CD15, CD11b, CD11c, CD56, CD34,
HLA-DR, HLA-A/B/C; anti-mouse CD45 and Ter119; and isotype con-
trol mAbs (all antibodies were purchased from BD PharMingen, San
Diego, CA). Analysis was performed on a LSR II (Becton Dickinson,
Mountain View, CA), and dead cells were excluded from the analysis
by gating out lower forward scatter and high propidium iodide or
DAPI-retaining cells. For making hu-mice with autologous leukemia,
NSG mice were injected with CD34+ FLCs that were transduced with
retroviral vectors containing MLL-AF9, and leukemia development
was assessed by FACS and histology.2.4. Cytospin and Histology Analysis
Bone marrow or spleen cells were prepared from leukemic hu-mice
and GFP+ human leukemia cells were puriﬁed by cell sorting,
suspended in PBS, and centrifuged (130 g for 5 min) onto glass slides
using a Cytospin centrifuge (Shandon). The slides were stained with
the DipQuick Stain Kit (modiﬁed Wright Giemsa staining) from
Jorgensen Laboratories. Tissues from leukemic hu-mice were ﬁxed in
10% buffered formalin and embedded in parafﬁn for hematoxylin and
eosin (H&E) staining. Stained slides were examined under a Zeiss mi-
croscope and photographed using a Nikon Coolpix 5000 digital color
camera.2.5. Hydrodynamic Gene Delivery
Human cytokine genes (IL-15/Flt-3L/GM-CSF/IL-3)were cloned sep-
arately into pcDNA3.1(+) vector (Invitrogen) (Chen et al., 2012; Chen
et al., 2009). Plasmid DNA was puriﬁed by Maxi-prep Kit (Qiagen),
and injected i.v. into hu-mice 12 days prior to RLI (5–50 μg of each plas-
mid in a total of 1.8-mL salinewithin 7 s using a 27-gauge needle) (Suda
et al., 2007).
2.6. In Vivo Human T Cell Depletion
Hu-mice were treated with 6 injections (i.v.) of anti-huCD3-
immunotoxin (a gift from Dr. David Neville (Woo et al., 2010)) with
the dose of 5 μg/Kg BID for 3 days (6, 5 and 4 days before RLI). Right be-
fore each day injections, blood sampleswere collected for FACS analysis.
Some hu-micewere sacriﬁced to conﬁrm the depletion of human T cells
in periphery and organs by FACS 3 days after the treatment was
completed.
2.7. Recipient Lymphocyte Infusions
Spleen cells were prepared fromRLI-cell source hu-mice and admin-
istered i.v. at a dose of 2–3 × 107 cells per mouse into hu-mouse chi-
meras 11–12 weeks after human CD34+ cell transplantation. In some
experiments, human CD25+ cells were depleted from RLI inoculum by
MACS using anti-human CD25 microbeads (Miltenyi Biotech, Aubum,
CA).
2.8. Statistical Analysis
The level of signiﬁcant differences in group means was deter-
mined by the Student's t-test for parametric data sets. The overall
difference between groups was determined by two-way ANOVA
with repeated measures. All analysis was performed using Prism 5
(GraphPad Software). A P value of ≤0.05 was considered signiﬁcant
in all analyses.
3. Results
3.1. Construction of HumanizedMiceWithHuman Immune System and Au-
tologous Leukemia
We transplanted sublethally-irradiated NSG mice with human
FTHY and CD34+ FLCs that were transduced with retrovirus contain-
ing a mixed-lineage leukemia (MLL) fusion gene MLL-AF9 (Barabe et
al., 2007) (Fig. 1a). FACS analysis revealed a gradual increase in the
levels of human PBMCs, including T and B cells and myeloid cells
(or APCs), with a similar kinetics as that seen in hu-mice receiving
untransduced CD34+ FLCs (Lan et al., 2006), until 15 weeks when
overt leukemia appeared (Fig. 1b). The hu-mice became moribund
between 19 and 24 weeks after transplantation (Fig. 1c); autopsy re-
vealed splenomegaly, enlarged lymph nodes, hepatomegaly, and en-
larged FTHY grafts in all of these mice (Fig. 1d and data not shown).
Histology demonstrated that leukemic cells inﬁltrated all organs/tis-
sues examined, including bone marrow, spleen, lung, liver, kidney,
and FTHY graft (Fig. 2a and data not shown). AsWright-Giemsa stain-
ing demonstrated, puriﬁed GFP+ cells exhibited a high nucleus/cyto-
plasm ratio (Fig. 2b), a typical leukemic blast morphology. The GFP+
leukemic cells present a B-ALL phenotype, i.e., CD19+CD10+CD20−-
sIgMlow/−sIgDlow/−CD44hiMHC-I+MHC-IIhi and negative for other
lineage markers i.e., CD33−CD15low/−CD14−CD11b−CD3−CD4− -
CD8−CD56− (Fig. 2c). Leukemia with a similar B-ALL phenotype
also developed in mice receiving MLL-AF9-transduced CD34+ FLCs
without FTHY (Table 1). Therefore, this leukemic hu-mouse model
not only establishes human lymphohematopoietic system, but also
Fig. 1.Generation of hu-micewith a functional human immune systemand autologous leukemia. (a) Schematic showing preparation of hu-mice. (b) Representative FACSproﬁles showing
the presence of human lymphohematopoietic cells and GFP+ leukemia cells. (c) Survival of leukemic (solid symbol; n = 5) and non-leukemic (open symbol; n = 4) hu-mice. (d)
Macroscopic evidence of tumor in lymph node and spleen (left) and sizes (mean ± SDs) of spleens from leukemic and non-leukemic hu-mice. *** P b 0.001.
Fig. 2. Characterization of leukemia developed in mice receivingMLL-AF9-transduced CD34+ cells. (a–c) Moribund leukemic hu-mice were sacriﬁced for histologic, morphologic and
phenotypic analysis. (a) Histologic (H&E) analysis of bone marrow (BM; top left), liver (top right), spleen (bottom left), and lung (bottom right); arrow indicates tumor area. (b)
Wright–Giemsa stained cytospins of puriﬁed GFP+ leukemia cells. (c) GFP+ leukemia cells characteristic of B-ALL phenotype in the indicated tissues. (d) Hu-mice were prepared by
transplantation of FTHY and CD34+ FLCs from the same fetus used to make the leukemic hu-mice. Fourteen weeks later, the hu-mice were either untreated or conditioned with 1 Gy
TBI, followed 1 day later by i.v. injection of 1 × 105 autologous leukemia cells (i.e., a 1:3 mixture of BM and spleen cells from the primary leukemic hu-mice; n = 4 per group). As
indicated in (c), the majority of BM and spleen cells were GFP+ leukemia cells. Shown are FACS analyses of GFP+ leukemia cells in PBMCs from representative mice.
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Table 1
Human B-ALL development in hu-mice receivingMLL-AF9-transduced CD34+ FLCs alone
or along with FTHY.
Group (n)
No. of hu-mice with human
engraftment








NSG mice were sublethally (2 Gy) irradiated, followed by transplantation of MLL-AF9-
transduced CD34+ FLCs (i.v.; 1 × 105 permouse) alone or alongwith FTHY (under the kid-
ney capsule). Human cell engraftment and B-ALL developmentwere assessed by FACS and
histology. Data from hu-mice made of human CD34+ FLCs and FTHY from 3 different fe-
tuses are combined.
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model to study human tumor immunology to autologous leukemia.
Bone marrow or spleen cells, when adoptively transferred into
sublethally-irradiated NSG mice, induced lethal leukemia in a cell
number-dependent manner (Fig. S1a–b). The leukemia cells were
also transplantable in hu-mice with an established autologous
human immune system (i.e., transplanted with FTHY and CD34+
FLCs from the same fetus from which CD34+ FLCs were used to
make the leukemic hu-mice), in which all recipient hu-mice showed
detectable GFP+ leukemia cells in blood within 2 weeks and died by
49 days following injection of 1 × 105 leukemia cells (Fig. 2d). In con-
trast, the leukemia cells were rejected in hu-mice with an allogeneicFig. 3. Lymphopenia promotes anti-donor alloresponses of RLI. (a) Schemeof the experimental d
‘recipient’ and 7.5 × 104 HLA-A2+ ‘donor’ CD34+ FLCs alone (lymphopenia), or along with HL
made by transplantation of HLA-A2− ‘recipient’ FTHY and CD34+ FLCs into NSG mice. (b) Lev
huCD45+ PBMCs. (d) Percentages of HLA-A2− ‘recipient’ CD4+ (Top) and CD8+ (Bottom
percentage of HLA-A2+ ‘donor’ cells in human CD19+ cell population. N = 4–6 per group a
two-way ANOVA with repeated measures.immune system, i.e., hu-mice made of FTHY and CD34+ FLCs from a
different fetus (Fig. S1c). Together, our data demonstrate that these
leukemia cells are transplantable in immune compromised recipi-
ents or recipients with autologous immune system, thereby offering
another means of creating hu-mice with a functional human
lymphohematopoietic system and autologous leukemia. These data
also demonstrate that human alloresponses can reject leukemia in
hu-mice.3.2. Lymphopenia Enhances Anti-leukemia Responses of Recipient Leuko-
cyte Infusion in Mixed Chimeric Hu-mice
Previous studies have shown that administration of recipient leuko-
cyte infusion (RLI) to mixed allogeneic chimeras results in loss of donor
hematopoietic chimerism and anti-host leukemia responses (Rubio et
al., 2003). Although the anti-leukemia response of RLI is signiﬁcantly
weaker than that of alloreactive donor leukocyte infusion (DLI) (Saito
et al., 2006), RLI does not induce GVHD, presenting a safe approach for
use in combination with other strategies of augmenting immune re-
sponses. Lymphopenia occurs frequently in patients with hematological
malignancies who receive allo-HCT (Heining et al., 2007; Small et al.,
1999) and promotes both antitumor responses (Dudley et al., 2002;
Quezada et al., 2010) and GVHD (Li et al., 2012; Miller et al., 2007).
Here we seek to employ lymphopenia to enhance antitumor responses
of RLI in a human immune system using the leukemic hu-mouse model
described above.esign. Hu-mouseMCswere prepared by transplantation of amixture of 2.5 × 104HLA-A2−
A-A2− ‘recipient’ FTHY (non-lymphopenia) into NSG mice. RLI-cell source hu-mice were
els of HLA-A2+ ‘donor’ chimerism. (c) Percentages of HLA-A2− ‘recipient’ CD3+ T cells in
) T cells expressing a effector/memory phenotype (i.e., CD45RA−CD45RO+). (e) The
t each time point; *P b 0.05; **P b 0.01 by the Student's t-test; #P b 0.05, ##P b 0.01 by
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pend on host-vs.-graft reaction (HVGR), which in turn provokes im-
mune responses to tumor-associated antigens expressed by
recipient leukemia cells (Rubio et al., 2005; Rubio et al., 2006).
Thus, we ﬁrst assessed the potential of lymphopenia to promote
HVGR. Non-lymphopenic MC controls were established by trans-
plantation of a mixture of ‘recipient’ (HLA-A2−) and allogeneic
‘donor’ (HLA-A2+) CD34+ FLCs, together with implantation of ‘re-
cipient’ FTHY. The hu-mice that received only a mixture of ‘recipient’
(HLA-A2−) and allogeneic ‘donor’ (HLA-A2+) CD34+ FLCs but no
implantation of FTHY developed few T cells and were regarded lym-
phopenic MCs. As elucidated in Fig. 3a, RLI cells are autologous/syn-
geneic to the ‘recipient’ and allogeneic to the ‘donor’ origin. To
establish a source of RLI cells, we created an additional group of
hu-mice by transplantation of HLA-A2− ‘recipient’ FTHY and
CD34+ FLCs into NSG mice. Unlike ‘recipient’ human T cells in the
MCs, which are tolerant of both the ‘recipient’ and ‘donor’ cells (Hu
and Yang, 2012), human T cells from the RLI-cell source hu-mice
should show tolerance to only the ‘recipient’, but not the ‘donor’ al-
loantigens and could therefore mediate anti-‘donor’ alloresponses
after injection into the MCs. Spleen cells were prepared from the
RLI-cell source hu-mice 11 weeks after transplantation, when signif-
icant human T cell reconstitution was established (Fig. S2), and
injected i.v. (i.e., RLI; 2 × 107/mouse) into hu-mouse MCs.
FACS analysis revealed successful reconstitution with human hema-
topoietic cells and the establishment of mixed human chimerism in hu-
mouse MCs (Figs. 3b and S3). Human T cells were barely detectable in
MCs that did not receive FTHY (i.e., Lymphopenic group; Figs. 3c and
S3). Comparing to that in the non-lymphopenic MCs, RLI T cells exhibit-
ed signiﬁcantly more robust activation in the lymphopenic MCs, shown
by a marked increase in the proportion of HLA-A2− ‘recipient’ CD3+ T
cells (Fig. 3c), and of ‘recipient’ CD4+ and CD8+ T cells expressing a
CD45RA−CD45RO+ effector/memory phenotype (Fig. 3d). After RLI,
lymphopenic, but not non-lymphopenic, MCs showed a rapid decline
in the levels of ‘donor’ (HLA-A2+) hematopoietic (CD45+) cells (Fig.
3b). To determine whether the decrease of ‘donor’ human chimerism
resulted from dilution due to the expansion of HLA-A2− RLI T cells, we
analyzed donor chimerism in the human B cell compartment. The ratios
of ‘donor’ (HLA-A2+) CD19+ B cells to ‘recipient’ in the lymphopenic
and non-lymphopenic MCs were comparable prior to RLI, but became
signiﬁcantly lower in the former than in the latter group after RLI (Fig.
3e). We conclude that lymphopenia signiﬁcantly enhanced RLI-mediat-
ed HVGR in MCs.
We next assessed the potential of lymphopenia to promote RLI-me-
diated anti-leukemia responses in MCs. Lymphopenia commonly seen
in leukemia patients who need HCT is mainly induced by conditioning
treatment and/or chemotherapy (Heining et al., 2007), and a lack of thy-
mic reserve (Small et al., 1999). Thus, to simulate lymphopenia in leuke-
mia patients, we depleted T cells by anti-huCD3-immunotoxin in the
hu-mouse MCs that had received a mixture of ‘recipient’ (HLA-A2+)
and allogeneic ‘donor’ (HLA-A2−) CD34+ FLCs with implantation of ‘re-
cipient’ FTHY (Fig. 4a).
We then enhanced RLI effects by manipulating APCs and regula-
tory T cells (Tregs) in the hu-mouse MCs. Although data presented
in Fig. 3 show that RLI mediated signiﬁcantly stronger HVGR in lym-
phopenic than in non-lymphopenic hu-mouse MCs, the response
was generally low in these mice, so as to be undetectable in the
non-lymphopenic MCs. Because RLI-mediated HVGR in mouseFig. 4. Lymphopenia promotes antitumor responses of RLI. (a) Experimental design. Hu-mous
6 × 104 HLA-A2− ‘donor’ CD34+ FLCs, plus HLA-A2+ ‘recipient’ FTHY into NSG mice, and used
human GFP− PBMCs (Left) and of HLA-A2−CD19+ ‘donor’ cells in human GFP−CD19+ cells (
human GFP− PBMCs. (d) CD45RA and CD45RO expression on HLA-A2+ ‘recipient’ CD3+ (to
(bottom) PBMCs. (e) Left, percentages of GFP+ leukemic cells in PBMCs; Right, absolute num
(bottom; numbers indicate the percentages of GFP+ leukemic cells in human CD45+ cells
Student's t-test; #P b 0.05, ###P b 0.001 by two-way ANOVA with repeated measures.models is largely dependent on donor APCs (Li and Sykes, 2012),
the weak alloreactivity of RLI in the hu-mice may be caused by low
numbers of APCs in the MCs. Thus, to boost humanmyeloid reconsti-
tution, we treated hu-mouse MCs with human cytokines 12 days
prior to RLI (Fig. 4a). The production of human cytokines (IL-15,
Flt-3L, GM-CSF and IL-3) in hu-mouse MCs was achieved by hydro-
dynamic injection of the cytokine-containing plasmids as previously
described (Fig. 4a) (Chen et al., 2009). Cytokine plasmid injection
signiﬁcantly increased reconstitution of human myeloid cells, in-
cluding human CD11c+CD14+, CD11c+CD14− and CD11c+HLA-
DR+ cells (Fig. S4). Another factor that may inhibit RLI-mediated
alloreactivity is the presence of relatively high levels of Tregs in the
RLI inoculum (Fig. S5). Therefore, we also depleted CD25+ cells
from RLI inoculum to enhance the RLI effect in the following experi-
ments (see below and Fig. S7a).
T cell lymphopenia was induced in hu-mouseMCs by i.v. injection
of anti-huCD3-immunotoxin (Woo et al., 2010) (5 μg/Kg BID for 3
consecutive days) starting 6 days prior to RLI (Fig. 4a). T-cell deple-
tion in MCs was conﬁrmed by FACS analysis (Fig. S6). RLI-cell source
hu-mice were made by transplantation of ‘recipient’ FTHY and
CD34+ FLCs as described above. After depletion of CD25+ human
Tregs (Foxp3+ cells were mainly in the CD4+CD25+ population,
Fig. S7a), the RLI source cells contained approximately 34% human
CD3+ T cells (with a CD4/CD8 ratio of about 3:1), in which most of
the cells expressed a naïve phenotype (Fig. S7b). These RLI source
cells were intravenously injected into hu-mouse MCs 4 days after
the last injection of anti-huCD3-immunotoxin (12 weeks after
FTHY/CD34+ FLC transplantation). Autologous leukemia cells were
given to the hu-mouse MCs 1 day prior to RLI in order to assess the
antitumor responses. Because anti-huCD3-immunotoxin has a very
short in vivo half-life (approximately 45 min) (Woo et al., 2010),
the conditioning treatment should not affect the function of RLI T
cells given 4 days after the treatment.
FACS analysis of blood cells revealed that RLI was signiﬁcantly
more effective in eliminating donor hematopoietic cells in the lym-
phopenic than in control MCs. As shown in Fig. 4b, the levels of
‘donor’ (HLA-A2−) CD45+ cells and CD19+ cells were comparable
between the control and lymphopenic MCs prior to RLI, but declined
signiﬁcantly more rapidly and extensively in the lymphopenic than
in control MCs. The average percentages of HLA-A2− ‘donor’ CD45+
cells in GFP− PBMCs of the control and lymphopenic MCs were 79%
vs. 79% 1 week prior to RLI, 75% vs. 45% 3 weeks post-RLI, and 52%
vs. 21% 6 weeks post-RLI, respectively. Similar changes were seen
in the CD19+ B cell population (Fig. 4b, right). The percentages of
HLA-A2+ ‘recipient’ T cells (including CD4+ and CD8+ subsets) in
total human GFP− PBMCs increased rapidly and extensively in MCs
with lymphopenia than in those without (Fig. 4c). Furthermore,
more human HLA-A2+ ‘recipient’ T cells (including both CD4+ and
CD8+ subsets) expressed a CD45RA−CD45RO+ activated/memory
phenotype in MC recipients with lymphopenia than in those without
(Fig. 4d). We conclude that lymphopenia signiﬁcantly enhances RLI
induced HVGR.
The stronger HVGR in the lymphopenic MCs was associated with an
increased antitumor response. FACS analysis of blood cells showed that
the percentages of leukemia cells at weeks 3 and 6 post-RLI were 1.4
and 5.5 fold higher, respectively, in control MCs than in lymphopenic
MCs (Fig. 4e, left). All mice were sacriﬁced at week 7 to measure leuke-
mia cell counts. As shown in Fig. 4e (right), the control MCs hade MCs were prepared by transplantation of a mixture of 4 × 104 HLA-A2+ ‘recipient’ and
as RLI recipients 12 weeks later. (b) Percentages of HLA-A2− ‘donor’ CD45+ cells in total
Right). (c) Percentages of the HLA-A2+ ‘recipient’ CD3+, CD4+ and CD8+ T cells in total
p) and percentages of CD45RA−CD45RO+ cells in HLA-A2+ ‘recipient’ CD4+ and CD8+
bers of GFP+ leukemic cells in BM and spleen (top) and representative FACS proﬁles
) at week 7 post-RLI (n ≥ 4 per group at each time point). *P b 0.05; **P b 0.01 by the
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107J. Xia et al. / EBioMedicine 10 (2016) 101–108signiﬁcantly more leukemia cells in the bone marrow and spleen than
lymphopenic MCs. These data indicate that lymphopenia can signiﬁ-
cantly enhance RLI-mediated anti-leukemia responses in MCs.
4. Discussion
We report a unique hu-mouse model that permits testing human
leukemia immunotherapy in recipients with functional human
lymphohematopoietic systems. In addition to hu-mice having both
normal human lymphohematopoietic systems and autologous leu-
kemia, this model also enables the production of non-leukemic hu-
mice with functional human lymphohematopoietic systems that
are autologous or allogeneic to the leukemia. Thus, this model has
potential for assessing adoptive immunotherapies using either au-
tologous or allogeneic effectors. This hu-mouse model offers, to our
knowledge, the only model available to date that permits in vivo
analysis of antitumor immune responses to autologous human can-
cers and evaluation of anti-leukemia therapies in the presence of a
human immune system. As an example, we recently conﬁrmed the
superiority of this model in testing and validating adoptive immuno-
therapy using autologous human T cells that are modiﬁed to express
anti-CD19 chimeric antigen receptors (CARs; data not shown).
MLL-AF9 has been found to be associated with both ALL and acute
myeloid leukemia (AML), butMLL-AF9 leukemia manifests more often
as ALL in infants, whereas almost always as AML in adults (Meyer et
al., 2013). Consistently, a previous mouse study suggests that the age
of HSCs is involved in the lineage determination ofMLL-AF9 leukemia,
asMLL-AF9 leukemia derived from adult mouse marrow HSCs was my-
eloid in character with myeloperoxidase (MPO) positivity and negative
for CD45R/B220, whereasMLL-AF9 leukemia derived from fetal mouse
liver HSCs was positive for CD45R/B220 and negative for MPO (Chen
et al., 2011). Thus, the use of fetal liver CD34+ cells might be a possible
reason for the observedpreference for B-ALL development in ourmodel.
However, our recent study showed that the lineage determination of
MLL-AF9-driven leukemia inmice is also largely affected by the cytokine
environment, as provision of human hematopoietic cytokines markedly
increased the chance of AML development from MLL-AF9-transduced
human CD34+ FLCs (unpublished data).
During allogeneic hematopoietic cell transplantation (allo-HCT),
donor T cellsmediate beneﬁcial graft-vs.-tumor (GVT) effects. However,
donor T cells also attack host normal tissues, resulting in graft-vs.-host
disease (GVHD). Intriguingly, antitumor responses and sustained remis-
sions of advanced chemo-refractory hematologic malignancies were
also seen in patients who rejected donor grafts after nonmyeloablative
allo-HCT (Dey et al., 2005). Mouse studies further demonstrated that
administration of RLI to mixed allogeneic chimeras results in loss of
donor hematopoietic chimerism and anti-host leukemia responses
(Rubio et al., 2003). Although RLI mediates signiﬁcantly weaker anti-
leukemia response than DLI (Saito et al., 2006), RLI does not induce
GVHD, presenting a safe approach for patients with a high risk of
GVHD. Our data show that the antitumor response of RLI can be signif-
icantly potentiated in lymphopenic recipients, indicating that RLI may
be a potential treatment option for leukemia patients with lymphope-
nia, an independent risk factor for GVHD following allo-HCT (Li et al.,
2012).
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